Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 Jul;39(1):63-74.
doi: 10.1016/j.cyto.2007.05.017. Epub 2007 Jul 20.

Regulation of HIV-1 latency by T-cell activation

Affiliations
Review

Regulation of HIV-1 latency by T-cell activation

Samuel A Williams et al. Cytokine. 2007 Jul.

Abstract

HIV-infected patients harbor approximately 10(5)-10(6) memory CD4 T-cells that contain fully integrated but transcriptionally silent HIV proviruses. While small in number, these latently infected cells form a drug-insensitive reservoir that importantly contributes to the life-long persistence of HIV despite highly effective antiviral therapy. In tissue culture, latent HIV proviruses can be activated when their cellular hosts are exposed to select proinflammatory cytokines or their T-cell receptors are ligated. However, due to a lack of potency and/or dose-limiting toxicity, attempts to purge virus from this latent reservoir in vivo with immune-activating agents, such as anti-CD3 antibodies and IL-2, have failed. A deeper understanding of the molecular underpinnings of HIV latency is clearly required, including determining whether viral latency is actively reinforced by transcriptional repressors, defining which inducible host transcription factors most effectively antagonize latency, and elucidating the role of chromatin in viral latency. Only through such an improved understanding will it be possible to identify combination therapies that might allow complete purging of the latent reservoir and to realize the difficult and elusive goal of complete eradication of HIV in infected patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
T-cell activation status influences establishment of active, preintegration- or postintegration latency. (A) HIV infection of unactivated, resting T-cells results in labile preintegration latency with unintegrated, cytoplasmasmic provirus. (B) Infection of activated T-cells results in integrated provirus and active infection with efficient production of progeny virions. (C) Infection of cells in the process of resolving T-cell activation permits completion of reverse transcription and integration, but fails to support active expression of viral genes, i.e. postintegration latency.
Figure 2
Figure 2
Signaling networks linking T-cell activating stimuli to HIV-inducing transcription factors. NF-κB, NFAT, and AP-1 mediate activation of latent HIV in response to cytokines, TCR ligation, and mitogens.
Figure 3
Figure 3
Molecular mechanisms of postintegration HIV-1 latency. Multiple mechanisms underlying HIV-1 latency have been observed in various models, including transcriptional interference by proximal promoters of host genes (A), exclusion of basal transcription factors from the HIV promoter by heterochromatin (B), or HDAC-mediated chromatin condensation (C), insufficiency of transcriptional coactivators (D), or basal nuclear export factors (E).

Similar articles

Cited by

References

    1. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature. 1997;387:188–91. - PubMed
    1. Chun TW, Davey RT, Jr, Ostrowski M, Shawn Justement J, Engel D, Mullins JI, et al. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat Med. 2000;6:757–61. - PubMed
    1. Davey RT, Jr, Bhat N, Yoder C, Chun TW, Metcalf JA, Dewar R, et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A. 1999;96:15109–14. - PMC - PubMed
    1. Schrager LK, D’Souza MP. Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. Jama. 1998;280:67–71. - PubMed
    1. Di Mascio M, Dornadula G, Zhang H, Sullivan J, Xu Y, Kulkosky J, et al. In a subset of subjects on highly active antiretroviral therapy, human immunodeficiency virus type 1 RNA in plasma decays from 50 to <5 copies per milliliter, with a half-life of 6 months. J Virol. 2003;77:2271–5. - PMC - PubMed